Jun 2026 (Q2 FY26) — Aug 6, 2026
10x Genomics Q2 FY26 — Atera Launch Exceeds Expectations, Driving Strong Order Flow
Read the full call10x Genomics (TXG) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
10x Genomics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 151 | −12.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -12.9 | −30.4 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -17.9 | −151.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 7 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Quarterly revenue (sequential change) | low-single-digit percentage sequential decline from Q1 FY26 | Mar 2026 | I wouldn't say that things have changed. In fact, I'd just remind you that the Q3 that we're talking about here is consistent with what we said in our Q1 call. | Achieved |
| Full-year revenue | $600 million to $625 million | Dec 2025 | We are raising our full year outlook and now expect 2026 revenue to be in the range of $610 million to $630 million. | Revised Up |
| Atera instrument shipments | approximately 40 units, with initial shipments beginning in the second half of 2026, weighted mostly toward Q4 | Mar 2026 | our shipment outlook of approximately 40 units for the year remains unchanged, as we continue ramping production. | On Track |
1 of 10x Genomics, Inc.'s 16 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 13 more targets are in the full ledger.
Claimed
- Q2 revenue, excluding nonrecurring settlement, grew 3% year-over-year to $149.4 million.
- Atera launch saw "extraordinary customer response" and "strikingly large number of orders" exceeding the full-year target of 40 units.
- Total consumables revenue increased 7% year-over-year, with Spatial consumables up 16% and Single Cell consumables up 3%.
- Gross margin, excluding nonrecurring settlement, expanded to 74% from 67% year-over-year.
- Ended the quarter with $552 million in cash, cash equivalents, and marketable securities, up $105 million year-over-year.
Qualified
- Instrument revenue declined 47% year-over-year, with Chromium down 46% and Spatial down 48%, primarily due to customers moderating purchases in anticipation of Atera.
- APAC revenue decreased 19% year-over-year, partly due to a prior-year pull-forward.
- Q3 revenue is expected to see a "modest sequential step down" from Q2 due to continued Spatial transition dynamics.
Price
$72.39 −0.97% · −$0.71
Performance +527.3% 1Y
1Y: $11.54 on 14 Oct 2025 → $72.39. High $97.74 (5 Oct 2026), low $11.54 (14 Oct 2025).
- Previous close
- $73.1
- 52-week range
- $11.54 – $97.74
- One year
- +508.83%
Overview
- Symbol
- TXG
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 7 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Quarterly revenue (sequential change) | low-single-digit percentage sequential decline from Q1 FY26 | Mar 2026 | I wouldn't say that things have changed. In fact, I'd just remind you that the Q3 that we're talking about here is consistent with what we said in our Q1 call. | Achieved |
| Full-year revenue | $600 million to $625 million | Dec 2025 | We are raising our full year outlook and now expect 2026 revenue to be in the range of $610 million to $630 million. | Revised Up |
| Atera instrument shipments | approximately 40 units, with initial shipments beginning in the second half of 2026, weighted mostly toward Q4 | Mar 2026 | our shipment outlook of approximately 40 units for the year remains unchanged, as we continue ramping production. | On Track |
Claimed
- Q2 revenue, excluding nonrecurring settlement, grew 3% year-over-year to $149.4 million.
- Atera launch saw "extraordinary customer response" and "strikingly large number of orders" exceeding the full-year target of 40 units.
- Total consumables revenue increased 7% year-over-year, with Spatial consumables up 16% and Single Cell consumables up 3%.
- Gross margin, excluding nonrecurring settlement, expanded to 74% from 67% year-over-year.
- Ended the quarter with $552 million in cash, cash equivalents, and marketable securities, up $105 million year-over-year.
Qualified
- Instrument revenue declined 47% year-over-year, with Chromium down 46% and Spatial down 48%, primarily due to customers moderating purchases in anticipation of Atera.
- APAC revenue decreased 19% year-over-year, partly due to a prior-year pull-forward.
- Q3 revenue is expected to see a "modest sequential step down" from Q2 due to continued Spatial transition dynamics.
The full ledger
Open 10x Genomics, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 16 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
10x Genomics Q1 FY26 — Atera Launch Exceeds Expectations, Driving Spatial Momentum
Read the full callEvery analysed call
10x Genomics earnings calls (TXG)
Financials
What the filings say
Net profit, year on year: −152% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 152 | 165 | 155 | 173 | 149 | 166 | 151 | 151 |
| Operating profit | -41 | -50 | -39 | 30 | -32 | -20 | -17 | -20 |
| Operating margin | −27.4% | −30.2% | −25.4% | 17.4% | −21.6% | −11.8% | −11.3% | −12.9% |
| Other income | 7 | 1 | 6 | 7 | 4 | 4 | 4 | 1 |
| Interest | 0 | 0 | 0 | 0 | -0 | 0 | — | 0 |
| Profit before tax | -34 | -48 | -34 | 37 | -28 | -15 | -13 | -19 |
| Tax rate | −3.8% | −1.3% | −2.5% | 6.7% | 2.6% | −7.0% | −4.8% | 3.8% |
| Net profit | -36 | -49 | -34 | 35 | -27 | -16 | -13 | -18 |
| EPS ($ per share) | -0.30 | — | -0.28 | 0.28 | -0.22 | — | -0.10 | -0.14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -231 | -262 | -805 | -863 | -1,029 | -1,284 | -1,467 | -1,511 |
| Total liabilities | 101 | 186 | 190 | 201 | 223 | 224 | 209 | 245 |
| Fixed assets | 11 | 49 | 73 | 169 | 289 | 280 | 253 | 227 |
| Total assets | 124 | 606 | 929 | 1,019 | 1,029 | 965 | 919 | 1,041 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -76 | 35 | -218 | -21 | -34 | -15 | 7 | 136 |
| Cash from investing | -7 | -43 | -38 | -107 | -351 | 133 | -33 | -13 |
| Cash from financing | 105 | 415 | 469 | 35 | 16 | 14 | 11 | 7 |
| Net cash flow | 22 | 406 | 212 | -93 | -369 | 132 | -15 | 130 |
| Capital expenditure | -6 | -43 | -37 | -101 | -132 | -49 | -12 | -6 |
| Free cash flow | -83 | -8 | -255 | -123 | -165 | -64 | -6 | 130 |
TXG revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Consumables | 83% | 81% | 74% | 71% | 86% | 85% | 86% | 87% | +7.0% |
| Chromium Consumables | 64% | 59% | 54% | 50% | 62% | — | 59% | 59% | +3.1% |
| Spatial Consumables | 20% | 22% | 20% | 21% | 24% | 25% | 27% | 28% | +16.2% |
| Service | 4% | 4% | 5% | 5% | 5% | 5% | 6% | 7% | +26.0% |
| Instruments | 13% | 15% | 10% | 8% | 8% | 9% | 7% | 5% | -47.2% |
| Spatial Instruments | 8% | 8% | 6% | 5% | 5% | 6% | 4% | 3% | -47.8% |
| Chromium Instruments | 5% | 7% | 4% | 3% | 3% | — | 3% | 2% | -46.1% |
| Licensing and Royalty Revenue | — | — | 11% | 16% | 1% | <1% | 1% | 1% | -93.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- Americas 56% ↓ 2 pt
- US 54% ↓ 2 pt
- EMEA 26% ↑ 2 pt
- Asia Pacific 17%
- CN 10%
- Asia Pacific Excluding China 7%
- Americas Excluding United States 2%
As TXG cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
63 filings between Nov 24, 2025 and Sep 22, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$16.88M
50 sales by 6 insiders
68% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 9
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Also filed: 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Saxonov Serge | — | $6.82M | Sep 22, 2026 |
| Taich Adam | — | $4.84M | Sep 9, 2026 |
| STUELPNAGEL JOHN R | — | $2.39M | Sep 3, 2026 |
| Hindson Benjamin J. | — | $1.46M | Aug 24, 2026 |
| SULIMAN SHEHNAAZ | — | $791.9K | Sep 22, 2026 |
| Teichmann Sarah A. | — | $579.4K | Aug 14, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 292 | $22.8K |
| Sep 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 2,800 | $230.6K |
| Sep 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 2,000 | $159.2K |
| Sep 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 9,300 | $752.4K |
| Sep 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 9,900 | $810.1K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 1,222 | $100.5K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 2,270 | $185.4K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 1,325 | $107.1K |
| Sep 22, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 614 | $48.8K |
| Sep 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $78.2K |
| Sep 9, 2026 | Taich Adam Chief Financial Officer | Sale 10b5-1 plan | 13,754 | $897.6K |
| Sep 9, 2026 | Taich Adam Chief Financial Officer | Sale 10b5-1 plan | 1,206 | $76.8K |
| Sep 9, 2026 | Taich Adam Chief Financial Officer | Sale 10b5-1 plan | 31,428 | $2.02M |
| Sep 3, 2026 | STUELPNAGEL JOHN R Director | Sale | 6,174 | $386.5K |
| Sep 3, 2026 | STUELPNAGEL JOHN R Director | Sale | 7,012 | $425.3K |
| Sep 3, 2026 | STUELPNAGEL JOHN R Director | Sale | 6,814 | $423.2K |
| Sep 1, 2026 | Saxonov Serge Chief Executive Officer | Gift | 100 | $0 |
| Aug 26, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 492 | $31.9K |
| Aug 26, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 3,500 | $220.6K |
| Aug 26, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 6,494 | $415.5K |
| Aug 24, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 1,646 | $105.3K |
| Aug 24, 2026 | Taich Adam Chief Financial Officer | Sale | 17,166 | $1.08M |
| Aug 24, 2026 | Hindson Benjamin J. See Remarks | Sale | 13,818 | $870.9K |
| Aug 24, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 561 | $35.2K |
| Aug 24, 2026 | Saxonov Serge Chief Executive Officer | Sale | 18,545 | $1.17M |
| Aug 20, 2026 | Saxonov Serge Chief Executive Officer | Gift | 4,000 | $0 |
| Aug 14, 2026 | Teichmann Sarah A. Director | Sale 10b5-1 plan | 2,273 | $129.9K |
| Aug 13, 2026 | Teichmann Sarah A. Director | Sale 10b5-1 plan | 5,278 | $302.4K |
| Aug 11, 2026 | STUELPNAGEL JOHN R Director | Sale | 17,000 | $978.9K |
| Aug 11, 2026 | STUELPNAGEL JOHN R Director | Sale | 3,000 | $176.2K |
| Jun 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 8,527 | $283.9K |
| Jun 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 1,661 | $60.1K |
| Jun 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 9,821 | $346.8K |
| Jun 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 9,991 | $342.5K |
| Jun 16, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 364 | $12.1K |
| Jun 16, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 5,359 | $174.6K |
| Jun 4, 2026 | SULIMAN SHEHNAAZ Director | Award | 8,829 | $0 |
| Jun 4, 2026 | Kosaraju Sridhar Director | Award | 8,829 | $0 |
| Jun 4, 2026 | STUELPNAGEL JOHN R Director | Award | 8,829 | $0 |
| Jun 4, 2026 | MATEO ALAN Director | Award | 8,829 | $0 |
| Jun 4, 2026 | Teichmann Sarah A. Director | Award | 8,829 | $0 |
| Jun 4, 2026 | Popovits Kimberly J Director | Award | 8,829 | $0 |
| May 26, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 10,718 | $264.8K |
| May 22, 2026 | Hindson Benjamin J. See Remarks | Sale | 11,595 | $283.4K |
| May 22, 2026 | Taich Adam Chief Financial Officer | Sale | 15,098 | $369.0K |
| May 22, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 18,175 | $444.2K |
| Apr 14, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 5,000 | $122.8K |
| Mar 24, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 5,000 | $97.6K |
| Mar 23, 2026 | Saxonov Serge Chief Executive Officer | Sale 10b5-1 plan | 10,000 | $191.3K |
| Mar 3, 2026 | Saxonov Serge Chief Executive Officer | Gift 10b5-1 plan | 2,750 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for 10x Genomics, Inc.
Free account. Everything above stays public.
Write why you follow 10x Genomics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading